LIVERSTAT TEST

Know Your Liver. Manage Your Risk.

Early Detection Saves Lives.

Your Life Matters Especially For You and Those You Love.

UNIQUE OFFERINGS

AI-Powered Liver Health Screening

Fast. Accurate. Non-Invasive.

• ✅ Driven by Artificial Intelligence
• 🩺 Designed for Metabolic Risk Patients
• 📊 Based on Routine Blood & Body Data

A clinical aid for steatotic liver disease and liver fibrosis. Formerly called NAFLD (Non-Alcoholic Fatty Liver Disease)

A non-invasive test powered by artificial intelligence, designed to screen and stratify risk in patients with metabolic dysfunction.

Serves as first-line clinical aid for advanced fibrosis and steatosis risk assessment in patients with metabolic syndrome (MetS).

• 80% of patients with NAFLD present with normal liver enzymes and are underdiagnosed
• Up to 56% develop NASH (Non-Alcoholic Steatohepatitis), especially with type 2 diabetes
• 1 in 3 patients with diabetes present with normal ALT despite advanced liver fibrosis
• A liver ultrasound is unable to stage liver fibrosis

Description:

Non-invasive test using blood and body data to detect liver scarring and fat.

Purpose:

More accurate fatty liver screening than standard ultrasound for at-risk patients.

MANAGING STEATOTIC LIVER DISEASE (NAFLD) RISK

Order for all MetS patients as first-line clinical aid

Receive report for:

• Class A – No presumed liver fibrosis. No presumed steatosis
• Class B – No presumed liver fibrosis. Presumed steatosis
• Class C – Presumed liver fibrosis, mild or moderate
• Class D – Presumed liver fibrosis, advanced (severe)

Determine the best patient management plan:

• Intensive lifestyle change
• MetS correction
• Referral to liver specialist
• Monitor progression with LIVERFAST